Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Novel p53 reactivators that are synergistic with olaparib for the treatment of gynecologic cancers with mutant p53

Translational Oncology(2025)10.1016/j.tranon.2025.102522Source: DataRank Database

Novel p53 reactivators that are synergistic with olaparib for the treatment of gynecologic cancers with mutant p53 is a research paper published in Translational Oncology (2025). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 3.05)OA: goldTopics (23)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Jamie L. Padilla,Angelina Licor,Mara P. Steinkamp ORCID,Irina V. Lagutina ORCID,Yan Guo ORCID

Live enrichment

PubMed:40915175 PMC:PMC12450570 OpenAlex:https://openalex.org/W4414031505

National Institutes of Health

Grant: P50CA264793

Congressionally Directed Medical Research Programs

Grant: CA210610

Congressionally Directed Medical Research Programs

Grant: CA2220729

National Institutes of Health

Grant: 5P30CA118100-05

CANCER CENTER RESEARCH ADMINISTRATION

National Institutes of Health

Grant: 7R01CA099908-19

Targeted Therapy for Endometrial Cancer

US Department of Defense

National Institutes of Health National Cancer Institute

FWCI

3.05

Citation Percentile

0.9%

Citation Trend

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.tranon.2025.102522

publisherhttps://doi.org/10.1016/j.tranon.2025.102522

publisherhttps://api.elsevier.com/content/article/PII:S1936523325002530?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1936523325002530?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40915175

Fields of Study

PARP inhibition in cancer therapyCancer-related Molecular PathwaysAdvanced Breast Cancer Therapies03 medical and health sciences0302 clinical medicine

Keywords

OlaparibMutantCancer researchMedicineOncologyChemistryGenePolymerasePoly ADP ribose polymeraseBiochemistryp53Ovarian cancerEndometrial CancerBrcaHo-3867Prima-1metApr-246Original Research